Glepaglutide
Sponsors
Zealand Pharma
Conditions
HealthyHealthy SubjectsRenal ImpairmentShort Bowel Syndrome
Phase 1
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
CompletedNCT03279302
Start: 2017-09-04End: 2017-12-18Updated: 2017-12-22
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function
CompletedNCT04178447
Start: 2019-12-10End: 2020-07-14Updated: 2020-11-18
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.
CompletedNCT04318743
Start: 2020-03-04End: 2021-06-10Updated: 2021-07-14
Phase 3
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
CompletedNCT03690206
Start: 2018-10-04End: 2022-07-26Updated: 2025-07-17
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
CompletedNCT03905707
Start: 2019-05-07End: 2026-04-30Updated: 2026-09-08
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
CompletedNCT04881825
Start: 2021-06-16End: 2026-04-30Updated: 2026-09-08
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
CompletedNCT04991311
Start: 2021-08-10End: 2023-09-05Updated: 2024-11-22
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RecruitingNCT07197944
Start: 2026-02-11End: 2032-02-28Target: 90Updated: 2026-08-12